New protocol for seminoma SWENOTECA IX

October 1, 2014

A new protocol for seminoma is now available. It replaces SWENOTECA VII from  October 1, 2014.

The major changes in the guideline are:

  • Stage I:

    • Patients with tumour size 4 cm or less and without invasion of the rete testis are recommended surveillance.

    • Patients with tumour size more than 4 cm or invasion of the rete testis are recommended adjuvant carboplatin. Surveillance may be an option to those patients not wanting adjuvant treatment.

  • Stage II A

    • ​Chemotherapy in the form of BEP x 3 or radiotherapy 2 Gy x 15 to 30 Gy to the para-aortic, the ipsilateral common iliac- and the external iliac lymph nodes may be used as primary treatment 

  • Stage II B-IV

    • The standard treatment is BEP x 3. In patients with contraindication to bleomycin EP x 4 should be used. 

  • Radiotherapy for cancer in situ (CIS) in the contralateral testicle:

    Many SWENOTECA centers have prescribed an average target dose of 16 Gy, 2 Gy x 8. And therefore a part of the testicle has got a dose < 16 Gy. There have been relapses after irradiation for CIS. Our new recommendation is therefore: The target dose should be average 18 Gy, 2 Gy x 9, in order to get a minimum dose of 17 Gy in the testicle. 

 

 

For full information see SWENOTECA IX

Tags:

Please reload

Featured Posts

Kjære SWENOTECA venner. Endelig program og invitasjon for årets stormøte er vedlagt. Møtet er på Gardermoen torsdag 4. april. Påmeldingsfrist er 19. m...

Annual meeting 2019

March 1, 2019

1/5
Please reload

Recent Posts

March 1, 2019

October 30, 2015

April 9, 2015

Please reload

Archive
Please reload

Search By Tags
Please reload

​​​Contact Us

SWENOTECA

Kreftklinikken, St. Olavs Hospital,

Postboks 3250 Sluppen

7006 Trondheim, Norway

Follow Us

  • w-facebook

swenoteca.org

 © 2015 SWENOTECA